- Home
- CCIF vs AGEN Comparison
CCIF vs AGEN Comparison
Compare CCIF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- AGEN
- Stock Information
- Founded
- CCIF 2011
- AGEN 1994
- Country
- CCIF United States
- AGEN United States
- Employees
- CCIF N/A
- AGEN N/A
- Industry
- CCIF Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCIF Finance
- AGEN Health Care
- Exchange
- CCIF Nasdaq
- AGEN Nasdaq
- Market Cap
- CCIF 110.5M
- AGEN 96.2M
- IPO Year
- CCIF N/A
- AGEN 2000
- Fundamental
- Price
- CCIF $8.01
- AGEN $2.92
- Analyst Decision
- CCIF
- AGEN Buy
- Analyst Count
- CCIF 0
- AGEN 3
- Target Price
- CCIF N/A
- AGEN $10.50
- AVG Volume (30 Days)
- CCIF 76.9K
- AGEN 551.7K
- Earning Date
- CCIF 01-01-0001
- AGEN 11-12-2024
- Dividend Yield
- CCIF 25.90%
- AGEN N/A
- EPS Growth
- CCIF N/A
- AGEN N/A
- EPS
- CCIF N/A
- AGEN N/A
- Revenue
- CCIF N/A
- AGEN $160,427,000.00
- Revenue This Year
- CCIF N/A
- AGEN N/A
- Revenue Next Year
- CCIF N/A
- AGEN $36.13
- P/E Ratio
- CCIF N/A
- AGEN N/A
- Revenue Growth
- CCIF N/A
- AGEN 59.00
- 52 Week Low
- CCIF $7.43
- AGEN $2.50
- 52 Week High
- CCIF $10.16
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- CCIF 41.94
- AGEN 41.32
- Support Level
- CCIF $8.12
- AGEN $2.73
- Resistance Level
- CCIF $8.25
- AGEN $3.85
- Average True Range (ATR)
- CCIF 0.07
- AGEN 0.29
- MACD
- CCIF 0.00
- AGEN -0.01
- Stochastic Oscillator
- CCIF 32.00
- AGEN 24.03
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing primarily in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting primarily of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).